Evicenter
Wegovy (semaglutide), All indications
Manufacturer
Novo Nordisk Inc.
Prescribing information
Wegovy (opens in a new tab)
Questions
33
Last updated

All questions

Safety: Wegovy (semaglutide), all indications

14 questions · 1 source

Warnings

Can Wegovy cause severe stomach side effects?

Can Wegovy be used with severe gastroparesis?

Does Wegovy increase heart rate?

Does Wegovy cause thyroid cancer (boxed warning)?

Who should not take Wegovy?

Can Wegovy cause pancreatitis?

Can Wegovy cause gallstones or gallbladder problems?

“Treatment with WEGOVY® is associated with an increased occurrence of cholelithiasis and cholecystitis. The incidence of cholelithiasis and cholecystitis was higher in WEGOVY® injection- treated pediatric patients aged 12 years and older than in WEGOVY® injection-treated adults. In randomized clinical trials in adults for weight reduction, cholelithiasis was reported by 1.6% of WEGOVY® injection-treated patients and 0.7% of placebo injection-treated patients, and by 2.5% of WEGOVY® tablet-treated patients and 1% of placebo tablet-treated patients. Cholecystitis was reported by 0.6% of WEGOVY® injection-treated adult patients and 0.2% of placebo- treated patients. In a clinical trial in pediatric patients aged 12 years and older for weight reduction, cholelithiasis was reported by 3.8% of WEGOVY® injection-treated patients and 0% placebo-treated patients. Cholecystitis was reported by 0.8% of WEGOVY® injection-treated pediatric patients and 0% placebo- treated patients [see Adverse Reactions (6.1)]. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in WEGOVY®-treated patients than in placebo-treated patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.” (opens the source at this quote in a new tab)

Can Wegovy cause low blood sugar (hypoglycemia)?

“WEGOVY® lowers blood glucose and can cause hypoglycemia. In a trial of WEGOVY® injection in adult patients with type 2 diabetes and body mass index (BMI) greater than or equal to 27 kg/m2 for weight reduction (Study 3), hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in more patients treated with WEGOVY® versus placebo [see Adverse Reactions (6.1)]. One episode of severe hypoglycemia (requiring the assistance of another person) was reported in one WEGOVY® treated patient versus no placebo-treated patients [see Clinical Studies (14.2)]. In glycemic control clinical trials, the risk of hypoglycemia was increased when semaglutide injection or tablet was used concomitantly with insulin or an insulin secretagogue (e.g., sulfonylurea). Patients with diabetes mellitus taking WEGOVY® in combination with insulin or an insulin secretagogue may have an increased risk of hypoglycemia, including severe hypoglycemia. The use of WEGOVY® in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes, monitor blood glucose prior to starting WEGOVY® and during WEGOVY® treatment. When initiating WEGOVY®, consider reducing the dose of concomitantly administered insulin or insulin secretagogue to reduce the risk of hypoglycemia [see Drug Interactions (7.1)].” (opens the source at this quote in a new tab)

Can Wegovy cause kidney problems?

Should Wegovy be stopped before surgery or anesthesia?

Can Wegovy cause allergic reactions?

Can Wegovy worsen diabetic retinopathy?

“In a 2-year trial with semaglutide 0.5 mg and 1 mg once-weekly injection in adult patients with type 2 diabetes and high CV risk, diabetic retinopathy complications (which was a 4-component adjudicated endpoint) occurred in patients treated with semaglutide injection (3%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (semaglutide injection 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide injection 0.7%, placebo 0.4%). In a trial of adult patients with type 2 diabetes and BMI greater than or equal to 27 kg/m2 for weight reduction (Study 3), diabetic retinopathy was reported by 4% of WEGOVY® injection-treated patients and 2.7% placebo-treated patients [see Clinical Studies (14.2)]. In a glycemic control trial evaluating a dose comparable to the 9 mg dose and the 25 mg semaglutide tablet dose in patients with type 2 diabetes, a similar proportion of patients in each dose group reported diabetic retinopathy related adverse reactions during the trial; 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide group, respectively, reported moderate-severe non-proliferative diabetic retinopathy events, and 0% and 0.4% reported proliferative retinopathy events, respectively. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.” (opens the source at this quote in a new tab)

What should be done after a Wegovy overdose?

Note: The OVERDOSAGE section starts on page 7 of the Prescribing Information and continues on page 8.

Side effects

Do antibodies to Wegovy affect how well it works?